JP2017512786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512786A5 JP2017512786A5 JP2016558347A JP2016558347A JP2017512786A5 JP 2017512786 A5 JP2017512786 A5 JP 2017512786A5 JP 2016558347 A JP2016558347 A JP 2016558347A JP 2016558347 A JP2016558347 A JP 2016558347A JP 2017512786 A5 JP2017512786 A5 JP 2017512786A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- trifluoromethyl
- benzamide
- fluoro
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 pyrazolopyrimidinyl Chemical group 0.000 claims 53
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000002431 hydrogen Chemical group 0.000 claims 17
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 15
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 229940053128 nerve growth factor Drugs 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- MPVRBTDECKCFEY-UHFFFAOYSA-N CC(N)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=C1)C1=CC=CC=C1 Chemical compound CC(N)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=C1)C1=CC=CC=C1 MPVRBTDECKCFEY-UHFFFAOYSA-N 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 206010067601 Dysmyelination Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- XUZRZKLRCQZFRE-UHFFFAOYSA-N 2-fluoro-4-methyl-N-[6-[2-(methylamino)-2-oxoethyl]-2-phenylindazol-3-yl]-5-pyrimidin-2-ylbenzamide Chemical compound CNC(=O)Cc1ccc2c(NC(=O)c3cc(c(C)cc3F)-c3ncccn3)n(nc2c1)-c1ccccc1 XUZRZKLRCQZFRE-UHFFFAOYSA-N 0.000 claims 1
- ITZLPHSULOBASY-UHFFFAOYSA-N 2-fluoro-N-[5-(hydroxymethyl)-2-phenylpyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide Chemical compound OCC1=NC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 ITZLPHSULOBASY-UHFFFAOYSA-N 0.000 claims 1
- ZJANXHIOPJZRFG-UHFFFAOYSA-N C(#N)C1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O Chemical compound C(#N)C1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O ZJANXHIOPJZRFG-UHFFFAOYSA-N 0.000 claims 1
- RVPFEMHDILVAKN-UHFFFAOYSA-N C(C)(=O)NCC=1C=C(C=CC1)N1N=C2C(N=CC=C2)=C1NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O Chemical compound C(C)(=O)NCC=1C=C(C=CC1)N1N=C2C(N=CC=C2)=C1NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O RVPFEMHDILVAKN-UHFFFAOYSA-N 0.000 claims 1
- CSIQWYJANFGMGW-UHFFFAOYSA-N C1(=CC=CC=C1)N1N=C2C(N=CC(=C2)C(=O)N)=C1NC(=O)C1=CC(=C(C=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound C1(=CC=CC=C1)N1N=C2C(N=CC(=C2)C(=O)N)=C1NC(=O)C1=CC(=C(C=C1)C(F)(F)F)C1=NC=CC=N1 CSIQWYJANFGMGW-UHFFFAOYSA-N 0.000 claims 1
- WYGHKVWQCCSHOV-UHFFFAOYSA-N CC(O)C1=CC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 WYGHKVWQCCSHOV-UHFFFAOYSA-N 0.000 claims 1
- MDANURKSLYFPRZ-UHFFFAOYSA-N CC(O)C1=CC2=C(NC(=O)C3=CC=C(C(=C3)C3=NN(C)C=C3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=C(NC(=O)C3=CC=C(C(=C3)C3=NN(C)C=C3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 MDANURKSLYFPRZ-UHFFFAOYSA-N 0.000 claims 1
- LLVGDVKKDXMYDS-UHFFFAOYSA-N CC(O)C1=CC2=NN(C(NC(=O)C3=C(Cl)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=NN(C(NC(=O)C3=C(Cl)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=C1)C1=CC=CC=C1 LLVGDVKKDXMYDS-UHFFFAOYSA-N 0.000 claims 1
- FHQGBHLHSCXWTJ-UHFFFAOYSA-N CC(O)C1=CC2=NN(C(NC(=O)C3=C(Cl)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2N=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=NN(C(NC(=O)C3=C(Cl)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2N=C1)C1=CC=CC=C1 FHQGBHLHSCXWTJ-UHFFFAOYSA-N 0.000 claims 1
- KFUMLBPRQSNFIS-UHFFFAOYSA-N CC(O)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=N1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=N1)C1=CC=CC=C1 KFUMLBPRQSNFIS-UHFFFAOYSA-N 0.000 claims 1
- CDGQZCLRDVGCPS-UHFFFAOYSA-N CC(O)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NN(C)C=C3)C(F)(F)F)=C2N=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NN(C)C=C3)C(F)(F)F)=C2N=C1)C1=CC=CC=C1 CDGQZCLRDVGCPS-UHFFFAOYSA-N 0.000 claims 1
- OHTZNYGIBTVDIF-UHFFFAOYSA-N CC(O)C1=NC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=NC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 OHTZNYGIBTVDIF-UHFFFAOYSA-N 0.000 claims 1
- BBERDCONFQXSPX-UHFFFAOYSA-N CN(C)CC1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O Chemical compound CN(C)CC1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O BBERDCONFQXSPX-UHFFFAOYSA-N 0.000 claims 1
- VXAVCZZIGYUMSQ-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 Chemical compound CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 VXAVCZZIGYUMSQ-UHFFFAOYSA-N 0.000 claims 1
- ZCNGBXMCQVZBFM-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)N)C1=CC=CC=C1 Chemical compound CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)N)C1=CC=CC=C1 ZCNGBXMCQVZBFM-UHFFFAOYSA-N 0.000 claims 1
- AXFSAIJYBOTAFJ-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C=CC(=CC12)C(=O)N)C1=CC=CC=C1 Chemical compound CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C=CC(=CC12)C(=O)N)C1=CC=CC=C1 AXFSAIJYBOTAFJ-UHFFFAOYSA-N 0.000 claims 1
- NRBMTQFGYWJGBX-UHFFFAOYSA-N ClC1=C(C(=O)NC=2N(N=C3C=2N=C(C=C3)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound ClC1=C(C(=O)NC=2N(N=C3C=2N=C(C=C3)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NRBMTQFGYWJGBX-UHFFFAOYSA-N 0.000 claims 1
- LNPFNUJPXPEIBG-UHFFFAOYSA-N ClC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(C)(C)O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound ClC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(C)(C)O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 LNPFNUJPXPEIBG-UHFFFAOYSA-N 0.000 claims 1
- BVMGHNSPKPYMDY-UHFFFAOYSA-N ClC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound ClC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 BVMGHNSPKPYMDY-UHFFFAOYSA-N 0.000 claims 1
- HNMGFURPOCLUBZ-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=1N=CC(=C2)C(=O)N)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=1N=CC(=C2)C(=O)N)C1=CC=CC=C1 HNMGFURPOCLUBZ-UHFFFAOYSA-N 0.000 claims 1
- GBNVSNXLEIWGNC-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=CC=CC=C1 GBNVSNXLEIWGNC-UHFFFAOYSA-N 0.000 claims 1
- VMRBTIOELUXXOS-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)NCCO)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)NCCO)C1=CC=CC=C1 VMRBTIOELUXXOS-UHFFFAOYSA-N 0.000 claims 1
- ODJPBHRPHYLZGR-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C2N=CC(=C3)C(C)(C)O)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C2N=CC(=C3)C(C)(C)O)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 ODJPBHRPHYLZGR-UHFFFAOYSA-N 0.000 claims 1
- IWURPFDWEVICJW-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=2C=NC(=C3)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=2C=NC(=C3)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 IWURPFDWEVICJW-UHFFFAOYSA-N 0.000 claims 1
- KUVFCTFHZSUVLM-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=2N=CC(=C3)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=2N=CC(=C3)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 KUVFCTFHZSUVLM-UHFFFAOYSA-N 0.000 claims 1
- JQEZBHLEXLABRF-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(=O)N)C2=C(C=CC=C2)C)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(=O)N)C2=C(C=CC=C2)C)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C JQEZBHLEXLABRF-UHFFFAOYSA-N 0.000 claims 1
- NDIAMNTZKTYHGQ-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C NDIAMNTZKTYHGQ-UHFFFAOYSA-N 0.000 claims 1
- DIJLWKUDISEUSD-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CNCCO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CNCCO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C DIJLWKUDISEUSD-UHFFFAOYSA-N 0.000 claims 1
- NCSKJOFRPAWSMQ-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NCSKJOFRPAWSMQ-UHFFFAOYSA-N 0.000 claims 1
- KUWWQOJJZDEENF-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 KUWWQOJJZDEENF-UHFFFAOYSA-N 0.000 claims 1
- ASVQVVFLEKIMIE-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC=23)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC=23)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 ASVQVVFLEKIMIE-UHFFFAOYSA-N 0.000 claims 1
- PVWWJVBOYHULJD-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=CC(=CC23)CCO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=CC(=CC23)CCO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 PVWWJVBOYHULJD-UHFFFAOYSA-N 0.000 claims 1
- DPFLQQUIFVLOJF-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=CC(=CC=23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=CC(=CC=23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 DPFLQQUIFVLOJF-UHFFFAOYSA-N 0.000 claims 1
- KXECLFFOKKSMQT-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=CC(=CC=23)CO)C2=NNC(=C2)C)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=CC(=CC=23)CO)C2=NNC(=C2)C)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 KXECLFFOKKSMQT-UHFFFAOYSA-N 0.000 claims 1
- AADZKIQXCDCINB-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=NC(=CC32)CO)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2N(N=C3C=NC(=CC32)CO)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C AADZKIQXCDCINB-UHFFFAOYSA-N 0.000 claims 1
- NIJMADWXVFTQKO-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3N=CC(=CC32)C(C)(C)O)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3N=CC(=CC32)C(C)(C)O)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NIJMADWXVFTQKO-UHFFFAOYSA-N 0.000 claims 1
- APOONGNZUGSHGT-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 APOONGNZUGSHGT-UHFFFAOYSA-N 0.000 claims 1
- VJJNXINELPSTKN-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=CC=CC=C1 VJJNXINELPSTKN-UHFFFAOYSA-N 0.000 claims 1
- DSHCMFAIYUYYRV-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C(=CC=CC12)C(=O)N)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C(=CC=CC12)C(=O)N)C1=CC=CC=C1 DSHCMFAIYUYYRV-UHFFFAOYSA-N 0.000 claims 1
- QSBXBHUEPYNQTB-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C1N=C(C=C2)C(=O)N)C2=CC=CC=C2 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C1N=C(C=C2)C(=O)N)C2=CC=CC=C2 QSBXBHUEPYNQTB-UHFFFAOYSA-N 0.000 claims 1
- ZYJJNZCNBOVLCR-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=C(C=CC=C2)C Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=C(C=CC=C2)C ZYJJNZCNBOVLCR-UHFFFAOYSA-N 0.000 claims 1
- HYSMHBHSBGHVHB-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=C(C=CC=C1)C Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=C(C=CC=C1)C HYSMHBHSBGHVHB-UHFFFAOYSA-N 0.000 claims 1
- YAOPRVSKJLEMOO-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)NCCO)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)NCCO)C1=CC=CC=C1 YAOPRVSKJLEMOO-UHFFFAOYSA-N 0.000 claims 1
- VETNEPBRBSGTPG-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 VETNEPBRBSGTPG-UHFFFAOYSA-N 0.000 claims 1
- VVZWYJXHLGUKAL-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NNC=C1)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)N)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NNC=C1)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)N)C1=CC=CC=C1 VVZWYJXHLGUKAL-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- FKUSMPPXJLOXCR-UHFFFAOYSA-N N-[5-(2,2-difluoro-1-hydroxyethyl)-2-phenylindazol-3-yl]-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide Chemical compound OC(C(F)F)C1=CC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 FKUSMPPXJLOXCR-UHFFFAOYSA-N 0.000 claims 1
- YLIPQRCSRJTFHZ-UHFFFAOYSA-N N-[6-(2-amino-2-oxoethyl)-2-phenylpyrazolo[4,3-b]pyridin-3-yl]-2-chloro-4-methyl-5-pyrimidin-2-ylbenzamide Chemical compound CC1=CC(Cl)=C(C=C1C1=NC=CC=N1)C(=O)NC1=C2N=CC(CC(N)=O)=CC2=NN1C1=CC=CC=C1 YLIPQRCSRJTFHZ-UHFFFAOYSA-N 0.000 claims 1
- HSZLGMGLKICUOQ-UHFFFAOYSA-N NCC=1C=CC2=C(N(N=C2C1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NN(C=C1)C)C(F)(F)F)F)=O Chemical compound NCC=1C=CC2=C(N(N=C2C1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NN(C=C1)C)C(F)(F)F)F)=O HSZLGMGLKICUOQ-UHFFFAOYSA-N 0.000 claims 1
- GXHGCXDPSFWOQQ-UHFFFAOYSA-N O=C1N(C(CN1)=O)CC=1C=2C(N=CC1)=C(N(N2)C2=CC=CC=C2)NC(C2=C(C=C(C(=C2)C2=NN(C=C2)C)C(F)(F)F)F)=O Chemical compound O=C1N(C(CN1)=O)CC=1C=2C(N=CC1)=C(N(N2)C2=CC=CC=C2)NC(C2=C(C=C(C(=C2)C2=NN(C=C2)C)C(F)(F)F)F)=O GXHGCXDPSFWOQQ-UHFFFAOYSA-N 0.000 claims 1
- KGAQXHWMFVCAJX-UHFFFAOYSA-N OC(C(F)F)c1ccc2c(NC(=O)c3cc(-c4ncccn4)c(cc3F)C(F)(F)F)n(nc2c1)-c1ccccc1 Chemical compound OC(C(F)F)c1ccc2c(NC(=O)c3cc(-c4ncccn4)c(cc3F)C(F)(F)F)n(nc2c1)-c1ccccc1 KGAQXHWMFVCAJX-UHFFFAOYSA-N 0.000 claims 1
- ZFLNPQMSUGXZTP-UHFFFAOYSA-N OC(C)(C)C1=CC=2C(N=C1)=C(N(N2)C2=CC=CC=C2)NC(C2=CC(=C(C=C2)C(F)(F)F)C2=NN(C=C2)C)=O Chemical compound OC(C)(C)C1=CC=2C(N=C1)=C(N(N2)C2=CC=CC=C2)NC(C2=CC(=C(C=C2)C(F)(F)F)C2=NN(C=C2)C)=O ZFLNPQMSUGXZTP-UHFFFAOYSA-N 0.000 claims 1
- UFPNZOKJIKFUGS-UHFFFAOYSA-N OC1(CC1)C1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O Chemical compound OC1(CC1)C1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O UFPNZOKJIKFUGS-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/074143 WO2015143652A1 (en) | 2014-03-26 | 2014-03-26 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| CNPCT/CN2014/074143 | 2014-03-26 | ||
| PCT/US2015/021952 WO2015148354A2 (en) | 2014-03-26 | 2015-03-23 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512786A JP2017512786A (ja) | 2017-05-25 |
| JP2017512786A5 true JP2017512786A5 (en:Method) | 2018-05-10 |
Family
ID=54193893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558347A Pending JP2017512786A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
| JP2016558339A Pending JP2017508766A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558339A Pending JP2017508766A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9862707B2 (en:Method) |
| EP (2) | EP3122345B1 (en:Method) |
| JP (2) | JP2017512786A (en:Method) |
| KR (2) | KR20160131119A (en:Method) |
| CN (2) | CN106456582A (en:Method) |
| AU (2) | AU2015236438A1 (en:Method) |
| CA (2) | CA2942957A1 (en:Method) |
| MX (2) | MX2016012483A (en:Method) |
| RU (2) | RU2016141647A (en:Method) |
| WO (3) | WO2015143652A1 (en:Method) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
| WO2018236856A1 (en) * | 2017-06-19 | 2018-12-27 | University Of Maryland, Baltimore | Car activator agents for cyclophosphamide-based treatments of cancer |
| EP3692052A4 (en) | 2017-10-04 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | INHIBITION BY SMALL MOLECULES OF THE TRANSCRIPTION FACTOR SALL4 AND ITS USES |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| PL4053128T3 (pl) * | 2017-12-15 | 2025-01-27 | Biohaven Therapeutics Ltd. | Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu |
| ES2965174T3 (es) | 2018-04-12 | 2024-04-11 | Bayer Ag | Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}heterociclilamida y compuestos similares como plaguicidas |
| KR102129114B1 (ko) * | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물 |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| EP3841098B1 (en) | 2018-08-22 | 2026-01-14 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN117567338A (zh) | 2019-10-09 | 2024-02-20 | 拜耳公司 | 作为农药的新的杂芳基三唑化合物 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| TW202134226A (zh) | 2019-11-18 | 2021-09-16 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之新穎雜芳基-三唑化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR20230010070A (ko) | 2020-02-26 | 2023-01-17 | 클루젠 (상하이), 인크. | 트로포미오신 수용체 키나제(trk) 분해 화합물 및 사용 방법 |
| WO2021197467A1 (zh) * | 2020-04-02 | 2021-10-07 | 上海华汇拓医药科技有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
| AR122141A1 (es) * | 2020-05-28 | 2022-08-17 | Lilly Co Eli | Inhibidor de trka |
| CN113666862B (zh) * | 2021-08-18 | 2024-05-31 | 山东大学 | 一种通过镍催化不对称硝化反应制备手性3-硝基吲哚类化合物的方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB599834A (en) * | 1943-04-08 | 1948-03-22 | Francolor Sa | Improvements in or relating to the manufacture of azodyestuffs |
| AU680370B2 (en) * | 1994-06-21 | 1997-07-24 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo(1,5-a)pyrimidine derivative |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| DE19946322A1 (de) | 1999-09-28 | 2001-03-29 | Bayer Ag | Verfahren zur Konditionierung von Ionenaustauscherharzen |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| AU4878601A (en) * | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| KR100713137B1 (ko) * | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
| ES2380054T3 (es) * | 2001-09-26 | 2012-05-08 | Pfizer Italia S.R.L. | Derivados de aminoindazol activos como inhibidores de quinasas, procedimientos para su preparación, y composiciones farmacéuticas que los contienen |
| US20030144518A1 (en) * | 2001-12-07 | 2003-07-31 | The Procter & Gamble Company | Process for preparing 3-acylamino-imidazo[1,2-a]pyridines |
| JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| PT2263692T (pt) | 2002-12-24 | 2018-11-28 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
| RU2342365C2 (ru) | 2003-05-01 | 2008-12-27 | Бристол-Маерс Сквибб Компани | Арилзамещенные пиразоламиды в качестве ингибиторов киназ |
| TWI635096B (zh) | 2003-07-15 | 2018-09-11 | 安美基公司 | 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體 |
| WO2005030128A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| US20050143384A1 (en) | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| WO2005085227A1 (en) * | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| WO2005110994A2 (en) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| BRPI0608160A2 (pt) | 2005-02-16 | 2010-11-09 | Astrazeneca Ab | anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado |
| EP1877057A1 (en) | 2005-04-27 | 2008-01-16 | AstraZeneca AB | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
| WO2006123113A2 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| EP1904452A2 (en) * | 2005-07-14 | 2008-04-02 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| CA2623500A1 (en) | 2005-10-13 | 2007-04-19 | Devgen N.V. | Kinase inhibitors |
| EP1959944A1 (en) | 2005-12-15 | 2008-08-27 | Shionogi Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
| CA2654898A1 (en) | 2006-07-07 | 2008-10-01 | Boehringer Ingelheim International Gmbh | New chemical compounds |
| US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| EP2155194B1 (en) | 2007-04-06 | 2015-01-21 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| GB0708188D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
| MX2009013213A (es) * | 2007-06-08 | 2010-03-30 | Abbott Lab | Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa. |
| PE20090837A1 (es) | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
| US20100240657A1 (en) | 2007-07-02 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| BRPI0814628B1 (pt) | 2007-07-20 | 2022-04-05 | Nerviano Medical Sciences S.R.L. | Derivados ativos de indazol substituídos como inibidores da quinase |
| PL2197849T3 (pl) | 2007-10-09 | 2013-05-31 | Merck Patent Gmbh | Pochodne n-(pirazolo-3-ylo)-benzamidowe jako aktywatory glukokinazowe |
| RS53350B (sr) * | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
| KR101048448B1 (ko) * | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN106336400A (zh) | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| JP2012522013A (ja) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| WO2011014775A1 (en) * | 2009-07-31 | 2011-02-03 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| RU2608611C2 (ru) * | 2009-11-05 | 2017-01-23 | Юниверсити Оф Нотр Дам Дю Лак | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ |
| PL2588475T3 (pl) | 2010-07-02 | 2015-10-30 | Gilead Sciences Inc | Inhibitory kinazy regulującej sygnał apoptozy |
| SG187209A1 (en) * | 2010-08-05 | 2013-03-28 | Amgen Inc | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase |
| DK2611785T3 (da) | 2010-09-01 | 2014-08-25 | Bayer Ip Gmbh | N-(tetrazol-5yl)- og n- (triazol-5-yl) arylcarboxylsyreamider og deres anvendelse som herbicider |
| KR20130141500A (ko) * | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| US9079859B2 (en) | 2011-01-21 | 2015-07-14 | Auckland Uniservices Limited | Synthetic lethal targeting of glucose transport |
| EP2673270A1 (en) | 2011-02-09 | 2013-12-18 | Syngenta Participations AG | Insecticidal compounds |
| CN103649076B (zh) | 2011-05-13 | 2015-09-09 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
| CN102796103A (zh) | 2011-05-23 | 2012-11-28 | 南京英派药业有限公司 | 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用 |
| EP2714668B9 (en) | 2011-05-23 | 2017-06-14 | Merck Patent GmbH | Thiazole derivatives |
| US9102673B2 (en) * | 2011-07-12 | 2015-08-11 | Merck Sharp & Dohme Corp. | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors |
| WO2013074518A1 (en) * | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| EA025352B1 (ru) * | 2011-12-12 | 2016-12-30 | Др. Редди'С Лабораториз Лтд. | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ТРОПОМИОЗИН-РЕЦЕПТОРНОЙ КИНАЗЫ (Trk) |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| EP2689779A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
-
2014
- 2014-03-26 WO PCT/CN2014/074143 patent/WO2015143652A1/en not_active Ceased
-
2015
- 2015-03-23 US US15/128,793 patent/US9862707B2/en active Active
- 2015-03-23 RU RU2016141647A patent/RU2016141647A/ru not_active Application Discontinuation
- 2015-03-23 AU AU2015236438A patent/AU2015236438A1/en not_active Abandoned
- 2015-03-23 JP JP2016558347A patent/JP2017512786A/ja active Pending
- 2015-03-23 EP EP15769224.5A patent/EP3122345B1/en active Active
- 2015-03-23 US US15/129,206 patent/US9862716B2/en active Active
- 2015-03-23 KR KR1020167029497A patent/KR20160131119A/ko not_active Withdrawn
- 2015-03-23 MX MX2016012483A patent/MX2016012483A/es unknown
- 2015-03-23 KR KR1020167029495A patent/KR20160132114A/ko not_active Withdrawn
- 2015-03-23 CA CA2942957A patent/CA2942957A1/en not_active Abandoned
- 2015-03-23 CN CN201580027484.1A patent/CN106456582A/zh active Pending
- 2015-03-23 JP JP2016558339A patent/JP2017508766A/ja active Pending
- 2015-03-23 AU AU2015236363A patent/AU2015236363A1/en not_active Abandoned
- 2015-03-23 WO PCT/US2015/022004 patent/WO2015148373A2/en not_active Ceased
- 2015-03-23 MX MX2016012481A patent/MX2016012481A/es unknown
- 2015-03-23 WO PCT/US2015/021952 patent/WO2015148354A2/en not_active Ceased
- 2015-03-23 CN CN201580027483.7A patent/CN106456581A/zh active Pending
- 2015-03-23 CA CA2942817A patent/CA2942817A1/en not_active Abandoned
- 2015-03-23 EP EP15769051.2A patent/EP3122344B1/en active Active
- 2015-03-23 RU RU2016141645A patent/RU2016141645A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512786A5 (en:Method) | ||
| RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2017508766A5 (en:Method) | ||
| JP2017512794A5 (en:Method) | ||
| JP2018519323A5 (en:Method) | ||
| JP2007519694A5 (en:Method) | ||
| JP2016517417A5 (en:Method) | ||
| JP2009524670A5 (en:Method) | ||
| JP2016526576A5 (en:Method) | ||
| KR20150132384A (ko) | 항암 및 항-증식 활성을 나타내는 n-아실-n''-(피리딘-2-일) 우레아 및 유사체 | |
| JP2017501234A5 (en:Method) | ||
| JP2016523911A5 (en:Method) | ||
| JP2009510161A5 (en:Method) | ||
| JP2017537948A5 (en:Method) | ||
| JP2016519685A5 (en:Method) | ||
| JP2014037426A5 (en:Method) | ||
| RU2009117475A (ru) | Соединения, модулирующие активность c-fms и/или c-kit, и их применения | |
| JP2012532931A5 (en:Method) | ||
| JP2014531449A5 (en:Method) | ||
| JP2018503673A5 (en:Method) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2017523223A5 (en:Method) | ||
| JP2020502230A5 (en:Method) | ||
| KR102128509B1 (ko) | 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도 | |
| JP7507749B2 (ja) | Ｎａｄｐｈオキシダーゼ阻害剤としての新規化合物 |